Optimization of mediastinal staging in potential candidates for stereotactic radiosurgery of the chest  by Sarwate, Devadatta et al.
Sarwate et al General Thoracic SurgeryOptimization of mediastinal staging in potential candidates for
stereotactic radiosurgery of the chestDevadatta Sarwate, MD,a Saiyad Sarkar, MD,a,b William S. Krimsky, MD,a,b Constantine M. Burgan, MD,a
Kalpesh Patel, MD,a Ruth Evans, RN, CNOR, OCN,a and Daniel P. Harley, MDbFrom th
Squa
Disclos
Read a
Surg
Receive
publi
Address
Frank
(E-m
0022-52
Copyrig
doi:10.1
G
T
SObjective: Patients with medically inoperable nonsmall-cell lung cancer generally have limited staging of the
mediastinum using computed tomography and combined positron emission tomography and computed tomog-
raphy, before stereotactic radiosurgery. Historical data have demonstrated the superiority of tissue sampling
techniques such as endobronchial ultrasonography and mediastinoscopy compared with imaging studies in
accurately determining the nodal stage.We believe, that at a minimum,mediastinal interrogation with endobron-
chial ultrasonography should be performed before patients undergo stereotactic radiosurgery.
Methods: A retrospective review of 59 consecutive patients undergoing bronchoscopic fiducial marker place-
ment as potential candidates for stereotactic radiosurgery was done. All these patients had undergone endobron-
chial ultrasonography to assess the mediastinum. Transbronchial needle aspirates were taken using standard
criteria defined by a lymph node size greater than 5 mm in diameter and/or in the appropriate lymph node drain-
age pathway. The biopsies were reviewed by the institution’s pathologists.
Results:Mediastinal lymph node specimens were not taken in 9 patients because they did not meet our criteria.
Of the 50 patients who underwent mediastinal lymph node sampling, 10 had evidence of nodal involvement. On
review, 2 of these 10 patients had evidence of mediastinal adenopathy on computed tomography. After excluding
those 2 patients, the mediastinal lymph nodes were positive for metastatic disease in 8 (16%) of 50 patients with-
out previous radiographic evidence of disease. These patients were previously thought to be suitable candidates
for stereotactic radiosurgery. Also 5 of 10 patients with endobronchial ultrasound-positive lymph nodes had had
positron emission tomography-negative findings in the mediastinum. Finally, 10% of the patients suspected to
have stage II or III were downstaged with endobronchial ultrasonography and considered for stereotactic
radiosurgery.
Conclusions: Endobronchial ultrasonography-transbronchial needle aspirates is more accurate than computed
tomography and positron emission tomography in staging the mediastinum, can be performed with minimal
morbidity, and should be considered for all patients considered candidates for stereotactic radiosurgery.
(J Thorac Cardiovasc Surg 2012;144:81-6)Effective treatment of lung cancer necessitates accurate di-
agnosis and staging. There is little disagreement that for pa-
tients considered for surgical resection of nonsmall-cell
lung cancer (NSCLC), staging, in most cases, necessitates
investigations other than computed tomography (CT) and
positron emission tomography (PET).1 A large cohort of
clinical stage IA patients with NSCLC exists who would
be unable to tolerate the rigors of a surgical resection. In
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The Journal of Thoracic and C(SBRT) systems can offer significant improvements in the
treatment and local control of stage IA and IB NSCLCs.2-4
At Franklin Square Hospital Center in Baltimore,Md, Cy-
berknife with Synchrony (Accuray Robotic Radiosurgery
Systems; Accuray, Sunnyvale, Calif) is used to treat medi-
cally inoperable stage IA and B NSCLC. This system
achieves significant improvements in local control rates in
patients with stage I NSCLC who were not candidates for
surgical resection.5,6 The use of SBRT in patients with
stage II, III, and IV NSCLC will be ineffective and
potentially harmful. For most lung tumors, the tracking
system of Cyberknife with Synchrony requires placement
of fiducial markers (FMs) placed in or near the tumor. We
have previously published our data regarding the efficacy
of FM placement using a combination of electromagnetic
navigational bronchoscopy and endobronchial ultrasono-
graphy (EBUS).7 It is critical to recognize that this method
has the advantage of performing EBUS interrogation of the
mediastinum at FM placement, allowing for the detection
of any unsuspected synchronous mediastinal and/or hilar
nodal disease spread. This results in more accurate stagingardiovascular Surgery c Volume 144, Number 1 81
TABLE 1. Patient characteristics
Characteristic Value
Age (y)
Mean 72.2
Range 52–91
Gender (n)
Male 33
Female 26
Additional comorbidities (n)
Cardiovascular 24
Other 7
Lung involved (n)
Right 35
Left 24
Tumor location (n)
Central 12
Peripheral 47
Abbreviations and Acronyms
CT ¼ computed tomography
FM ¼ fiducial marker
PET ¼ positron emission tomography
EBUS ¼ endobronchial ultrasonography
NSCLC ¼ nonsmall-cell lung cancer
SBRT ¼ stereotactic body radiotherapy
SRS ¼ stereotactic radiosurgery
TBNA ¼ transbronchial needle aspiration
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Sbut potentially alters the treatment approach in patients
with existing nodal disease and in patients with false-
positive lymph node involvement on CT and PET scans.
The present study evaluated our experience using the de-
ployment of ultrasound interrogation of the mediastinum in
patients with clinical stage IA, IB, and II NSCLC at FM
placement to achieve accurate disease staging and to ensure
optimal treatment.METHODS
From June 2009 to July 2010, 59 consecutive patients (Table 1) who
were considered medically inoperable and had histologically proven clin-
ical stage I NSCLC were evaluated for treatment by a multidisciplinary
lung cancer tumor board at the Franklin Square Hospital Center. The tumor
board members included physicians from the departments of thoracic sur-
gery, pulmonary medicine, thoracic oncology, and pathology, and treat-
ment recommendations were achieved by a majority consensus. After
review, the patients who were potential candidates for SBRT according
to the CT and PET staging and poor physiologic status were referred for
FM placement. The age range of these patients was 52 to 91 years (mean
age, 72.2 years). Of the 59 patients, 33 were men and 26 were women.
The institutional review board of MedStar Health, the parent corporation
of Franklin Square Hospital Center, approved the data collection and anal-
ysis of these patients and waived patient consent for the present review.
All patients had undergone noncontrast-enhanced CT scans of the chest
configured with 1-mm by 1-mm slices in the Digital Imaging and Commu-
nications in Medicine format. All patients had undergone whole body PET
scans. All the studies were reviewed by an independent radiologist for the
present study and by an independent radiologist for the lung cancer tumor
board. Patients with unequivocal evidence of metastatic disease were not
considered for SBRT to the lung. The PET scans were all PET-CT scans
and were all performed at 1 imaging facility. The CT scans were all per-
formed at the Franklin Square Hospital Center.
All procedures were performed separately by 2 interventional pulmo-
nologists with extensive experience in both EBUS and electromagnetic
navigational bronchoscopy. The procedures were performed with the
patient under a light general anesthetic administered orally and chosen
by the anesthesiologist. All patients were positioned on an electromagnetic
location board at the beginning of each procedure. EBUS was performed
using an adult 3.0-mm working channel adult bronchoscope with an
EBUS probe. Our technique for using electromagnetic navigational bron-
choscopy, EBUS, and FM placement and confirmation has been previously
described.7 At FM placement, EBUS was used to interrogate the mediasti-
num, and the International Association for the Study of Lung Cancer lymph
node stations were scanned distally to proximally, starting in the hilum and
moving proximally, followed by interrogation of the subcarinal, pre- and
postcarinal nodes, and paratracheal nodes.82 The Journal of Thoracic and Cardiovascular SurgeWe used generally accepted criteria for lymph node sampling.8 The
lymph nodes with a short axis diameter greater than 5 mm were identified
and sampled, providing they were in the appropriate distribution for drain-
age from the suspect lesion. A 21- or 22-gauge transbronchial needle aspi-
ration (TBNA) needle was inserted into each of these areas and a specimen
obtained. Separate needles were used for each station to avoid the potential
of cross-contamination. A cytopathologist was available to assess the
adequacy of the aspirated material at surgery, but the final diagnosis was
deferred until the material had been reviewed by 2 separate histopatholo-
gists. Smaller lymph nodes suspicious for metastatic spread on EBUS
were also aspirated. This was performed at the discretion of the endoscop-
ist. Negative nodes were defined by the presence of benign anthracotic tis-
sue and negative flow cytometry analysis findings.RESULTS
All patients in the present study were classified inopera-
ble. In most cases, this was because of advanced pulmo-
nary disease. This was defined by the pulmonary
function test results. Those patients with a forced expira-
tory volume in 1 second of less than 40% of predicted
and a diffusion capacity of the lung of less than 40% of
predicted were considered to have severe obstructive
lung disease.9 In addition to their existing pulmonary dis-
ease, 24 patients (40%) had cardiovascular disease and 7
had other comorbidities; most were stroke and/or other ma-
lignancies. Of the 59 patients, 16 (27%) were octogenar-
ians with poor functional reserve due to age-related
disability. NSCLC was diagnosed in 58 patients, and 1 pa-
tient, suspected to have early-stage NSCLC and considered
a potential candidate for SBRT, was diagnosed with small
cell lung cancer from an EBUS-directed biopsy. Twelve
patients had local recurrence after previous surgical resec-
tion. One patient had undergone a previous pneumonec-
tomy. Of the 59 tumors, 35 were located on the right and
24 on the left; 12 tumors were central in location and 47
were peripheral. The mean tumor size was 2.7 cm. All pa-
tients underwent disease staging using the 7th edition TNM
staging system.ry c July 2012
TABLE 3. Lymph node stations by EBUS-TBNAwith result
Lymph node station Positive Negative
2L 0 3
4R 3 7
4L 0 6
7 8 32
10L 3 6
10R 1 11
11L 0 3
11R 0 4
12L 0 1
12R 1 3
Regional lymph node involvement
Mediastinal (N2 nodes) 11 48
Hilar (N1 nodes) 5 28
EBUS, Endobronchial ultrasonography; TBNA, transbronchial needle aspiration;
L, left; R, right.
FIGURE 1. Flow of participants through each stage of selection process.
SBRT, Stereotactic body radiotherapy; CT, computed tomography; PET,
positron emission tomography; EBUS, endobronchial ultrasonography;
TBNA, transbronchial needle aspiration.
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SEBUS was performed at FM placement in all patients.
Lymph node biopsies were not taken in 9 patients, 7 of
whom had failed to meet the criteria identified previously
for EBUS sampling. Of the remaining 2 patients, 1 did
not undergo lymph node sampling because of tortuous air-
ways and 1 because of the presence of an endoluminal tu-
mor (Figure 1).
A total of 92 lymph nodes were biopsied, 59 in the medi-
astinum and 33 in the hila (Tables 2-4). Of the 50 patients
who underwent EBUS-directed biopsies, 10 (20%) hadTABLE 2. EBUS-TBNA positive pathologic findings compared with
CT and PET findings in mediastinum
Pt. no. CT report PET report Tumor location
Stations positive
on pathologic
examination
1 Negative Negative Peripheral 7, 10L
2 Negative Negative Central 4R, 7
3 Negative Negative Peripheral 4R, 10R
4 Negative Positive Central 7, 10L
5 Negative Positive Peripheral 7
6 Negative Positive Peripheral 7
7 Negative Positive Peripheral 4R
8 Negative Negative Peripheral 7
9 Positive Negative Peripheral 7
10 Positive Positive Peripheral 7, 12R
EBUS, Endobronchial ultrasonongraphy; TBNA, transbronchial needle aspiration;
CT, computed tomography; PET, positron emission tomography; Pt. no., patient num-
ber; L, left; R, right.
The Journal of Thoracic and Cevidence of mediastinal lymph node involvement according
to the pathology results. On further review of the CT results,
2 of those 10 patients were believed to have equivocal find-
ings on the CT scan suggestive of mediastinal lymph node
enlargement. After excluding those patients from the anal-
ysis, the percentage of unexpected positive results de-
creased to 16.6% (8/48 patients). Additionally, occult
(PET/CT-negative) disease was present in roughly 10% of
these patients (5/48). Also, 4 patients with PET-positive
scans, who would have been excluded from treatment on
the basis of those results, were found to not have metastatic
nodal spread, defined as the absence of malignant cells in
the presence of small bland lymphocytes or fragments of
benign lymphoid tissue on histopathologic examination.
All patients tolerated the procedure well. No anesthesia-
related complications occurred. Some patients had blood-
streaked sputum after EBUS-TBNA; however, no patients
were readmitted to the hospital. No pneumothoraces devel-
oped, and all patients were discharged in stable condition.
DISCUSSION
After the tissue diagnosis of inoperable NSCLC has been
established or with patients in whom the clinical suspicion
is high and stereotactic radiosurgery (SRS) is recommen-
ded, consideration must turn toward the determination of
the disease extent, or stage, because this has a direct effect
on the management and prognosis. From the availableTABLE 4. Comparison of imaging results with EBUS pathologic
findings in mediastinum (n ¼ 50)
Variable EBUS positive EBUS negative
CT positive 2 9
CT negative 8 31
PET positive 5 4
PET negative 5 36
EBUS, Endobronchial ultrasonography; CT, computed tomography; PET, positron
emission tomography.
ardiovascular Surgery c Volume 144, Number 1 83
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Spublished data,10-13 these patients typically undergo limited
staging of the mediastinum by CT and PET.
CT scanning of the chest has a sensitivity and specificity
of 51% and 86% for identifying mediastinal lymph nodes
metastasis, respectively, when the nodes are greater than
1 cm in the short-axis diameter. In patients with clinical
T1N0 tumors, nodal metastasis can be missed in 5% to
15% of cases using CT evaluation of the mediastinum.14
Given the limitations of its sensitivity and specificity, it
would be unfortunate to rely solely on CT scanning for
the evaluation of mediastinal lymph nodes in the patient se-
lection for SRS.
PET is more accurate than CT in detecting mediastinal
lymph node metastasis. The sensitivity and specificity has
been found to be 74% and 85%, respectively. However,
this is also not ideal for several reasons. PET has limited an-
atomic and spatial resolution, with the lower limit of size
approximately 7 mm to 10 mm. Also, no standardized quan-
titative criteria are available for what constitutes an abnor-
mal PET finding in the mediastinum. Specifically, it is
difficult to differentiate between malignant and non-
neoplastic conditions such as granulomatous, inflammatory,
or infectious disease. Furthermore, false-positive PET find-
ings can occur in 25% of patients with enlarged mediastinal
nodes. This can lead to the denial of the optimal treatment
strategy. In contrast, false-negative PET findings can lead
to inappropriate treatment. In a meta-analysis by Gould
and colleagues,15 20% of patients with normal-size nodes
but with malignant involvement had false-negative PET
findings.
EBUS-TBNA has a sensitivity of 89%, specificity of
100%, and negative predictive value of 98.9% in patients
with negative CT and PET findings for nodal metastasis.16
Compared with surgical staging in patients with clinical
stage I tumors, it has also been found to have comparable
results.
At our institution, we have adopted the clinical practice
of investigating the mediastinum with EBUS at broncho-
scopic FM placement in patients considered for SRS by
our multidisciplinary tumor board. We believe that the me-
diastinum should be investigated using EBUS-TBNA. We
do not routinely perform mediastinoscopy in this group of
patients, because EBUS-TBNA is a less-invasive procedure
and has the advantage of being able to assess more nodal
stations than mediastinoscopy, including N1 nodes. We
acknowledge that the current published false-negative rate
for EBUS-TBNA is greater than that of mediastinoscopy,
although, again, as noted, these 2 modalities have been
found to have comparable results for stage I tumors.
Our results have confirmed the dissonance among CT,
PET, and EBUS-TBNA in accurately staging the mediasti-
num. Its results are comparable to, and in the case of occult
N1 disease superior to, those of mediastinoscopy. Of the pa-
tients in the present study who were scheduled for SRS,84 The Journal of Thoracic and Cardiovascular Surge16% were upstaged by diagnosing occult mediastinal
spread. These patients were re-evaluated for alternative
treatment modalities because SRS alone would clearly
have been suboptimal in these settings. Patients with posi-
tive PET findings should also always undergo invasive stag-
ing of the mediastinum to ensure they are not denied
optimal treatment. This was highlighted in that just less
than 50% (4/9) of patients with PET positive findings in
the mediastinum were downstaged such that they became
eligible for SRS. A bronchoscopic approach to staging the
mediastinum also allows other procedures to be performed
in the same session. A biopsy of lesions is 1 such advantage.
In 1 of our patients, the lesion yielded small cell lung can-
cer, resulting in a change in management.
Our study also raises the question of the accuracy of pre-
vious SRS studies performed without any invasive medias-
tinal staging. EBUS-TBNA will increase the accuracy of
future studies evaluating SRS, including both FM and
FM-less systems.CONCLUSIONS
The use of EBUS-TBNA should be considered for all pa-
tients being evaluated for SRS. It is highly accurate in all
patients with and without mediastinal lymph node enlarge-
ment on CTand with or without PET activity in the medias-
tinum. It is an appropriate choice for the primary procedure,
because it is well tolerated, carries minimal morbidity, and
allows for additional pulmonary procedures in the same
setting.
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DrRichard I.Whyte (Stanford, Calif).Dev, congratulations on
a nice presentation, and thank you for sending me the manuscript
in advance.
I have a couple of comments, and the questions I will put at the
end.
I think this study nicely complements the paper we heard this
morning about EBUS versus mediastinoscopy. Here, you used
these patients who were undergoing bronchoscopic FM place-
ment as your platform for this technique, and I think it should
be noted that the use of FMs is clearly decreasing. As the technol-
ogy of SBRT is getting better and better, the need for FMs is de-
creasing, and perhaps that will affect whether you do this, but I
suspect not.
The focus of this paper, obviously, is on PET and CT. In this
study, you used 5 mm as an indication for biopsy, and I was not re-
ally clear from the manuscript what you used as your criteria for
PET and CT, whether it was 10 mm or 5 mm in the short-axis di-
ameter or what the standard uptake value was. Interestingly, you
had flow cytometry as a criteria for being negative, and it would
be interesting to know whether that plays a significant role. But I
think, overall, you do indicate about a 15% false negative rate
for mediastinal node disease, and that is in keeping with the pub-
lished data. On a couple of your slides, however, I noticed that you
called the PET and CT findings false positives, and I think on 1
slide, you said that 9 of 11 had a false-positive rate on CT and 4
of 9 on PET. I think this assumes that your EBUS is actually truly
negative, and we do not really know that because we do not have
pathologic confirmation, and I suppose these false-positive PET
and CT findings could, in fact, be false-negative EBUS studies.
In general, I think that your conclusion that EBUS does upstage
and downstage some tumors in some patients is absolutely correct.
I think as to whether it is absolutely necessary, particularly in this
cohort of fairly sick patients, and whether that affects survival is
somewhat unclear. We do not have survival data, and often their
survival is more limited by their comorbidities.The Journal of Thoracic and CEssentially my questions are: What was the effect of flow cy-
tometry here? Was that really necessary, and did it affect which
findings were truly called negative? What were your criteria for
calling them abnormal on CT?Was it 5 mm, which I think is some-
what unconventional, or was it really 10 mm, which I think is
a more conventional number. Would you agree that some of these,
quote, ‘‘false positive’’ CT scans might, in fact, be false-negative
EBUS tests?
Overall, I enjoyed the paper. Thank you.
Dr Krimsky. Thank you very much.
The issuewith respect to the CT scans, I think, to be clear, it was
when the radiologist interpreting the CT scans called them
enlarged, and it was typically using a short-axis diameter of
10 mm or 1 cm. I do not think the flow cytometry helped very
much, for what that is worth.
Dr Shrager. What was the third question, Richard?
Dr Whyte. Some of these, quote ‘‘false-positive’’ and ‘‘false-
negative’’ CT and PET scans, could they really be false-negative
EBUS tests?
Dr Krimsky. Certainly. We have another study we are in the
process of finishing the data collection for to study the mediastinal
results and EBUS results at our particular institution, because data,
much like politics, is all local, and at least from the data we have so
far, the correlation rate is nearly perfect. Thus, I think the answer is
yes and yes, if that helps.
Dr Mark J. Krasna (Towson, Md). I will just follow-up with
that. That was a good presentation.
Bill, I guess I will put the question back to you as a comment. I
think your group has done a great job, especially since the Society
for Thoracic Surgery meeting, incorporating mediastinal nodal
staging. Similar to Dr Whyte, we are using FM-less systems;
thus, we do not need to perform bronchoscopy for that reason;
however, as you have trained us, we are using EBUS and mediasti-
noscopy. Thus, my only question is, have you or your surgical col-
league, Dr Harley, considered using mediastinoscopy for those 4
potential EBUS false-negative findings? Again, I think it is crucial,
and we do that for all our patients. If we have an EBUS-negative
finding, the patient undergoes mediastinoscopy; however, if it is
positive, wewill not have the patient undergo SRS because it might
be inappropriate therapy. Has that been done yet?
Dr Krimsky. I think had we not done the additional interroga-
tion and studied our mediastinal data comparing 1 test, at least at
our institution, with the other, than I think yes, but, however, the
data seem to be consistent. I think, again, it does bring up the
idea of stageN1 disease, because, as best I can tell, if you are beam-
ing something over here and you have a hilar node down here, it is 2
separate things altogether. I hope that answers the question.
Dr Hiran C. Fernando (Boston, Mass). Congratulations on the
presentation. I think this is really important to be doing in patients
who are going to be treated with nonoperative therapies.
In the abstract, you say that there is a 16% false-negative rate,
but you are talking only about CT staging, yet you presented
data on PET. Thus, if you combine the CT and PET information,
what is your true false-negative rate, and how much of that
false-negative rate is N1 disease and how much of that false-neg-
ative rate is N2 disease?
Dr Sarwate.With the PET scan, we had a false-negative rate of
10% and a false-negative rate of about 16% with the CT scan.ardiovascular Surgery c Volume 144, Number 1 85
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disease on pathologic examination.
Dr Fernando. So, if you combine the CTand the PET informa-
tion together, what is your true false-negative rate, using the best
clinical staging that you would have up to this point?
Dr Sarwate. That would be around 8%.
DrMeyers. I am going to turn it around a little bit. Dr Fernando,
you are the primary investigator for the very important American
College of Surgeons Oncology Group/Radiation Therapy Oncology
Group trial that is openingvery soon, randomizingbetweenSBRT, as
discussed here, and sublobar resection. What sort of mediastinal
evaluation are you requiring for that study that is opening soon?
Dr Fernando. Doing something like this would be perfect for
the study, but I do not think we could really mandate that in all
the sites, because 1 of the problems is patient accrual, and this
study is going to be a 422-patient study, and to have all sites doing
EBUS for every patient would not be practical. It would be perfect
if we could do this.
Dr Meyers. So CT and PET?
Dr Fernando.We are doing CTand PETand then invasive me-
diastinal staging or EBUS or endoscopic ultrasonography for those
lymph nodes that look suspicious by CT and/or PET.
Dr Paul Van Schil (Edegem, Belgium). Thank you for indeed
for stressing a very important point, because radiation oncologists
do not always pay enough attention to the lymph nodes.
I have 2 questions. You discovered N1 disease in some patients.
Would you consider adding chemotherapy to the radiotherapy for
those patients?
Dr Krimsky.Granted, there is a lot of controversy with that sit-
uation right now. I think we have left that to the discretion of the
medical oncologists, but it is certainly an interesting consideration,
especially in this patient population.
Dr Van Schil. Second, how far should you gowith this staging?
Current guidelines state that when you have negative EBUS find-
ings and a suspicious lymph node on CTor PET, you should go for
an invasive staging procedure. Would you consider mediastino-
scopy in some patients to include the mediastinum in the radiation
field in case you find N2 disease?
Dr Krimsky. I think that brings us back to Dr Krasna’s ques-
tion. We had been doing that, but we then looked at the data gen-
erated from mediastinoscopy, as well as the data generated from
EBUS, and, given the correlation, it seemed to be reasonable to
proceed at that point with just the EBUS findings alone. In addi-
tion, again, N1 disease is not picked up, so you are stuck with ei-
ther thoracoscopy or something else if you are looking at the hilar.
Dr Joseph B. Shrager (Stanford, Calif). I would like to make
a brief comment.
It is interesting that the radiation oncologists have moved in
general before SBRT to using just PET to decide what their fields
are going to be, and in a number of places, that is all they do. So we
have to kind of bring them back and remind them that they should
not be doing that with SBRT and that they are using an absolutely86 The Journal of Thoracic and Cardiovascular Surgeuseless therapy if they have not evaluated themediastinal nodes for
patients who are at any risk of having mediastinal nodal disease.
DrMeyers.You can say that, but their failure rate is not 16%. It
is much lower than that in patients they have selected. So, there
might be some paradox going on with the kinder immune response
after SBRT, but they do not fail at that high rate.
Dr Shrager. It is possible.
Dr JoachimSchirren (Wiesbaden, Germany).Excellent results.
You showed us that the staging in the mediastinum, with all the
technical aspects, is never correct; therefore, the question: What
will you do with the high-risk patient who receives SBRT? My
question is, could you imagine that video-assisted mediastino-
scopic lymphadenectomy or transcervical extended mediastinal
lymphadenectomy could be the right treatment of this patient,
that we have a very good resection of the lymph nodes without
compromising the patient, and then this procedure will be better
for this high-risk patient?
Dr Krimsky. In other words, surgery versus—perhaps I did not
understand the question.
DrSchirren. I think the nodes, they are never cleared completely;
therefore, perform video-assisted mediastinoscopic lymphadenec-
tomy or transcervical extended mediastinal lymphadenectomy and
resect the nodes. This is not compromising for the patient. You
have thenodes resected.Youhave avery good staging, better staging,
just as with EBUS. I like EBUS, but not in such cases, and then you
can send this patient for SBRT.
Dr Krimsky. Perhaps, yes.
Dr Shrager. Are you familiar with video-assisted mediastino-
scopic lymphadenectomy and transcervical extended mediastinal
lymphadenectomy, these methods of minimally invasively resect-
ing all the nodes?
Dr Krimsky. Yes.
Dr Kazuhiro Yasufuku (Toronto, Ontario, Canada). Thank
you very much for the excellent presentation.
I have 1 comment and 1 question. I think the point that we can
get N1 nodes is a big value of EBUS, because with SBRT, we can
assess the mediastinum with mediastinoscopy, but we cannot get
the N1 nodes with mediastinoscopy. From the results of your ret-
rospective study, what would your recommendations be for per-
forming EBUS for patients who are considered for SBRT?
Would you do EBUS for all patients, regardless of the CT or
PET findings, or would you just include patients who have positive
CT or PET findings?
Dr Krimsky. I think that is a great question, but I think actually
our results bear out what is in fact generally accepted in terms of the
size/staging in terms of the lesion itself. We are finding a number of
these are in lesions that are 2 cmorgreater, but those 2 cmor less,we
find a lot fewer. So, I think right now it seems that that guideline and
that suggestion still seems to hold a lot of value. Again, it is another
procedure. I think what Drs Whyte and Krasna also brought up is,
you know, do you need FMs, and this just happened to be something
that was concomitant for us. I hope that answers the question.ry c July 2012
